JPMorgan initiates Antengene stock coverage with Overweight rating
PositiveFinancial Markets

JPMorgan has started coverage of Antengene, a biopharmaceutical company, with an Overweight rating, indicating strong confidence in its future performance. This is significant as it highlights the potential growth and investment opportunities within the biotech sector, particularly for Antengene, which is focused on innovative cancer therapies.
— Curated by the World Pulse Now AI Editorial System